ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK Will Shutter Sirtris R&D Labs

by Michael McCoy
March 18, 2013 | APPEARED IN VOLUME 91, ISSUE 11

GlaxoSmithKline will close the Cambridge, Mass., labs of Sirtris, a biotech firm it acquired in 2008 for $720 million. The labs employ about 60 people, some of whom may relocate to GSK labs in the Philadelphia area. Sirtris is developing sirtuins, compounds thought to activate a biological pathway linked to antiaging effects. Resveratrol, a component of red wine, was the first sirtuin it explored, but the company stopped clinical trials after some patients developed kidney failure. A GSK spokeswoman says Sirtris continues to pursue next-generation sirtuins and that the move to GSK labs will take the effort to the next phase.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment